• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease

cafead

Administrator
Staff member
  • cafead   Jul 30, 2024 at 11:42: AM
via Back-to-back failures in psoriasis and Crohn’s disease have forced Ventyx Biosciences to abandon the development of its investigational oral TYK2 inhibitor VTX958.

article source